Low-dose thrombolysis for submassive pulmonary embolism.

Area of Science:

• Cardiology
• Pulmonology
• Thrombosis Research

Background:

• Submassive pulmonary embolism (PE) carries a risk of mortality and hemodynamic decompensation.
• The use of thrombolysis in submassive PE is debated due to potential bleeding complications.
• Current treatment guidelines for intermediate-risk PE often exclude thrombolytic therapy.

Purpose of the Study:

• To evaluate the efficacy and safety of half-dose tissue-type plasminogen activator (rt-PA) in treating submassive PE.
• To determine if a reduced dose of rt-PA can prevent death or hemodynamic decompensation without increasing hemorrhage risk.
• To compare outcomes of half-dose rt-PA plus low molecular weight heparin (LMWH) versus LMWH alone in intermediate-risk PE.

Main Methods:

• Prospective, non-randomized, open-label, single-center trial.
• Inclusion criteria: submassive PE with echocardiographic or CT angiography evidence of right heart strain.
• Comparison groups: 50 mg rt-PA + LMWH vs. LMWH alone; primary outcome: death/hemodynamic decompensation at 7 and 30 days; safety outcome: major extracranial bleeding/hemorrhagic stroke at 7 days.

Main Results:

• Significantly lower rates of death or hemodynamic decompensation at 7 and 30 days in the half-dose rt-PA group (p=0.028 and p=0.009).
• No significant difference in recurrent embolism or pulmonary hypertension at 6-month follow-up.
• No intracranial hemorrhage observed; no significant difference in major or minor bleeding complications between groups.

Conclusions:

• Half-dose rt-PA is effective in preventing early death or hemodynamic decompensation in submassive PE.
• This treatment strategy offers a potential benefit without a significant increase in bleeding risk.
• Half-dose rt-PA represents a viable therapeutic option for selected intermediate-risk PE patients.